Kenneth Erland Johnson - 29 Jan 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Signature
/s/ Beth Hecht, as Attorney-in-Fact
Issuer symbol
XERS
Transactions as of
29 Jan 2022
Net transactions value
-$146,264
Form type
4
Filing time
09 Aug 2024, 16:07:06 UTC
Previous filing
05 Jan 2022
Next filing
01 Feb 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability $15,819 -7,497 -1.7% $2.11* 440,443 29 Jan 2022 Direct F1, F2, F3
transaction XERS Common Stock Tax liability $4,868 -2,307 -0.52% $2.11* 438,136 31 Jan 2022 Direct F1, F4
transaction XERS Common Stock Tax liability $13,888 -12,400 -2.8% $1.12 425,736 03 Jan 2023 Direct F1, F5
transaction XERS Common Stock Tax liability $13,897 -11,029 -2.6% $1.26 414,707 29 Jan 2023 Direct F1, F6
transaction XERS Common Stock Tax liability $4,207 -3,393 -0.82% $1.24 411,314 31 Jan 2023 Direct F1, F7
transaction XERS Common Stock Tax liability $27,776 -12,400 -3% $2.24 398,914 03 Jan 2024 Direct F1, F8
transaction XERS Common Stock Tax liability $28,587 -10,747 -2.7% $2.66 388,167 29 Jan 2024 Direct F1, F9
transaction XERS Common Stock Tax liability $37,222 -15,131 -3.9% $2.46 373,036 31 Jan 2024 Direct F1, F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction is being reported late due to administrative oversight.
F2 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2022.
F3 These shares include 1,080 shares that were purchased on June 30, 2024 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.
F4 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2022.
F5 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2023.
F6 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2023.
F7 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2023.
F8 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 3, 2024.
F9 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 29, 2024.
F10 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of RSUs vested as of January 31, 2024.

Remarks:

Senior Vice President, Global Development and Medical Affairs